| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 38 | 2018 | 379 | 4.630 |
Why?
|
| Myeloproliferative Disorders | 19 | 2016 | 146 | 2.940 |
Why?
|
| Leukemia, Myeloid, Acute | 33 | 2018 | 825 | 1.820 |
Why?
|
| World Health Organization | 20 | 2016 | 121 | 1.780 |
Why?
|
| Bone Marrow | 48 | 2018 | 408 | 1.740 |
Why?
|
| Chromosome Aberrations | 39 | 2012 | 348 | 1.490 |
Why?
|
| Leukemia | 20 | 2017 | 300 | 1.270 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 10 | 2009 | 175 | 1.160 |
Why?
|
| Leukemia, Hairy Cell | 31 | 1994 | 72 | 1.030 |
Why?
|
| Leukemia, Myeloid | 25 | 2016 | 240 | 1.010 |
Why?
|
| Primary Myelofibrosis | 13 | 2010 | 67 | 0.970 |
Why?
|
| Lymphoma | 14 | 2009 | 247 | 0.910 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2009 | 110 | 0.680 |
Why?
|
| Polycythemia Vera | 7 | 2009 | 22 | 0.600 |
Why?
|
| Thrombocythemia, Essential | 6 | 2009 | 16 | 0.560 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 86 | 0.560 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 99 | 0.530 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2018 | 663 | 0.520 |
Why?
|
| Humans | 188 | 2019 | 93132 | 0.520 |
Why?
|
| Azacitidine | 1 | 2018 | 149 | 0.510 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 38 | 0.490 |
Why?
|
| Trans-Activators | 3 | 2018 | 439 | 0.480 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 636 | 0.460 |
Why?
|
| Translocation, Genetic | 21 | 2014 | 245 | 0.440 |
Why?
|
| Acute Disease | 26 | 2017 | 838 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 1999 | 260 | 0.410 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 2301 | 0.410 |
Why?
|
| Blood Cells | 4 | 2012 | 32 | 0.400 |
Why?
|
| Hypergammaglobulinemia | 1 | 2013 | 7 | 0.390 |
Why?
|
| Erythropoiesis | 4 | 2011 | 52 | 0.390 |
Why?
|
| Histiocytosis, Sinus | 1 | 2013 | 17 | 0.390 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 2 | 2009 | 12 | 0.380 |
Why?
|
| Plasma Cells | 1 | 2013 | 84 | 0.370 |
Why?
|
| Hodgkin Disease | 6 | 1998 | 144 | 0.350 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2012 | 422 | 0.340 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 465 | 0.340 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 18 | 0.330 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 255 | 0.330 |
Why?
|
| Prognosis | 34 | 2014 | 3890 | 0.330 |
Why?
|
| Histones | 1 | 2013 | 361 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 8 | 6 | 2004 | 83 | 0.320 |
Why?
|
| Male | 102 | 2015 | 44355 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 339 | 0.310 |
Why?
|
| Karyotyping | 36 | 2006 | 220 | 0.300 |
Why?
|
| Mutation | 10 | 2009 | 4265 | 0.300 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 555 | 0.290 |
Why?
|
| Female | 96 | 2019 | 48542 | 0.280 |
Why?
|
| Middle Aged | 85 | 2019 | 27535 | 0.280 |
Why?
|
| Chromosome Disorders | 11 | 1995 | 97 | 0.280 |
Why?
|
| Genome, Human | 2 | 2013 | 823 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2014 | 2543 | 0.280 |
Why?
|
| Diagnosis, Differential | 12 | 2009 | 1519 | 0.280 |
Why?
|
| Lymphoproliferative Disorders | 6 | 2000 | 104 | 0.270 |
Why?
|
| Aged | 71 | 2014 | 20395 | 0.270 |
Why?
|
| Cytarabine | 10 | 2012 | 217 | 0.270 |
Why?
|
| Hematologic Neoplasms | 7 | 2015 | 372 | 0.270 |
Why?
|
| Adult | 89 | 2014 | 27849 | 0.260 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 537 | 0.260 |
Why?
|
| Blast Crisis | 4 | 2008 | 37 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 21 | 6 | 2004 | 53 | 0.240 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2003 | 147 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 5 | 5 | 2009 | 113 | 0.220 |
Why?
|
| Interferon Type I | 10 | 1992 | 163 | 0.220 |
Why?
|
| Methylation | 2 | 2018 | 288 | 0.220 |
Why?
|
| Terminology as Topic | 3 | 2012 | 219 | 0.210 |
Why?
|
| Algorithms | 4 | 2009 | 1948 | 0.200 |
Why?
|
| Burkitt Lymphoma | 3 | 2004 | 32 | 0.200 |
Why?
|
| Trisomy | 6 | 2002 | 53 | 0.200 |
Why?
|
| Guidelines as Topic | 3 | 2012 | 163 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2016 | 133 | 0.190 |
Why?
|
| Adolescent | 29 | 2014 | 9550 | 0.190 |
Why?
|
| Daunorubicin | 7 | 2012 | 77 | 0.180 |
Why?
|
| Interferon-alpha | 5 | 1994 | 187 | 0.180 |
Why?
|
| Lymphatic Diseases | 3 | 2013 | 31 | 0.180 |
Why?
|
| Antigens, Neoplasm | 5 | 1990 | 356 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 2 | 2009 | 172 | 0.170 |
Why?
|
| Aged, 80 and over | 19 | 2014 | 7039 | 0.160 |
Why?
|
| Survival Analysis | 12 | 2008 | 1518 | 0.160 |
Why?
|
| Chromosomes, Human, 16-18 | 7 | 1984 | 16 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 3 | 2003 | 244 | 0.160 |
Why?
|
| Composite Lymphoma | 1 | 2019 | 2 | 0.150 |
Why?
|
| Cell Lineage | 5 | 2016 | 321 | 0.150 |
Why?
|
| Chromosome Inversion | 6 | 2014 | 45 | 0.150 |
Why?
|
| Lymph Nodes | 10 | 2013 | 550 | 0.150 |
Why?
|
| Chromosome Deletion | 10 | 2009 | 213 | 0.150 |
Why?
|
| Classification | 3 | 2006 | 55 | 0.150 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2018 | 79 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 281 | 0.140 |
Why?
|
| Mastocytosis | 3 | 2016 | 14 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 1995 | 100 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2008 | 80 | 0.140 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 3 | 0.140 |
Why?
|
| Histiocytes | 2 | 1998 | 22 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 7 | 0.140 |
Why?
|
| GATA1 Transcription Factor | 1 | 2018 | 19 | 0.140 |
Why?
|
| Child, Preschool | 9 | 2013 | 3781 | 0.140 |
Why?
|
| Antigens, Differentiation | 4 | 1991 | 124 | 0.130 |
Why?
|
| Etoposide | 6 | 2010 | 205 | 0.130 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 61 | 0.130 |
Why?
|
| Hematopoiesis | 5 | 2015 | 183 | 0.130 |
Why?
|
| Remission Induction | 12 | 2012 | 737 | 0.130 |
Why?
|
| Infant | 3 | 2013 | 3156 | 0.130 |
Why?
|
| Cytosine | 1 | 2018 | 121 | 0.130 |
Why?
|
| Bone Marrow Examination | 6 | 2009 | 40 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2008 | 360 | 0.120 |
Why?
|
| Hematopoietic System | 3 | 2009 | 12 | 0.120 |
Why?
|
| Spleen | 7 | 2001 | 372 | 0.120 |
Why?
|
| Methyltransferases | 1 | 2018 | 212 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2014 | 940 | 0.120 |
Why?
|
| Anemia | 3 | 2009 | 129 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 556 | 0.120 |
Why?
|
| Philadelphia Chromosome | 1 | 1996 | 44 | 0.120 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 6 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1993 | 113 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2009 | 1660 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 22 | 4 | 2004 | 40 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 409 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2018 | 1687 | 0.110 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1995 | 7 | 0.110 |
Why?
|
| Child | 13 | 2013 | 7273 | 0.110 |
Why?
|
| Eosinophilia | 3 | 2016 | 87 | 0.110 |
Why?
|
| Preleukemia | 2 | 2009 | 10 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 440 | 0.110 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2014 | 9 | 0.110 |
Why?
|
| Chromosomes, Human, 6-12 and X | 6 | 1986 | 13 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 621 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 215 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 1998 | 295 | 0.100 |
Why?
|
| Protein Binding | 1 | 2018 | 1526 | 0.100 |
Why?
|
| Abnormal Karyotype | 1 | 2014 | 8 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 33 | 0.100 |
Why?
|
| Splenectomy | 7 | 1988 | 46 | 0.100 |
Why?
|
| Bone Marrow Cells | 7 | 2015 | 264 | 0.100 |
Why?
|
| Alkaline Phosphatase | 5 | 1988 | 128 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 113 | 0.100 |
Why?
|
| Leukocyte Count | 10 | 2015 | 209 | 0.100 |
Why?
|
| Methotrexate | 2 | 2012 | 226 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 109 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 740 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2012 | 456 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2014 | 1517 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2008 | 319 | 0.100 |
Why?
|
| Megakaryocytes | 4 | 2008 | 38 | 0.100 |
Why?
|
| Sclerosis | 1 | 2013 | 31 | 0.100 |
Why?
|
| T-Lymphocytes | 6 | 2014 | 1276 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2004 | 80 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 139 | 0.090 |
Why?
|
| Cyclosporins | 2 | 2010 | 56 | 0.090 |
Why?
|
| Vidarabine | 2 | 2003 | 93 | 0.090 |
Why?
|
| Mastocytosis, Systemic | 2 | 2009 | 13 | 0.090 |
Why?
|
| Anemia, Refractory | 3 | 1996 | 5 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2004 | 85 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2013 | 710 | 0.090 |
Why?
|
| Janus Kinase 2 | 2 | 2009 | 59 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2757 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 296 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2005 | 278 | 0.090 |
Why?
|
| fas Receptor | 1 | 2012 | 73 | 0.090 |
Why?
|
| Neutropenia | 3 | 2007 | 209 | 0.090 |
Why?
|
| Recombinant Proteins | 11 | 1996 | 981 | 0.090 |
Why?
|
| Splenomegaly | 3 | 2004 | 19 | 0.090 |
Why?
|
| Erythropoietin | 3 | 1997 | 90 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1997 | 158 | 0.080 |
Why?
|
| Biopsy | 8 | 2014 | 1172 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 241 | 0.080 |
Why?
|
| Follow-Up Studies | 13 | 2014 | 3814 | 0.080 |
Why?
|
| Leukemia, Monocytic, Acute | 3 | 1987 | 9 | 0.080 |
Why?
|
| Survival Rate | 6 | 2012 | 1945 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 1231 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1925 | 0.080 |
Why?
|
| Treatment Outcome | 15 | 2010 | 9070 | 0.080 |
Why?
|
| Interferons | 3 | 1990 | 112 | 0.080 |
Why?
|
| Gene Expression | 2 | 2009 | 1304 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 12 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 1910 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 27 | 0.080 |
Why?
|
| Eosinophils | 3 | 1986 | 194 | 0.080 |
Why?
|
| Hematinics | 1 | 2009 | 11 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 54 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2001 | 78 | 0.080 |
Why?
|
| Thalidomide | 1 | 2009 | 53 | 0.070 |
Why?
|
| Topotecan | 1 | 2009 | 46 | 0.070 |
Why?
|
| Cell Count | 1 | 2009 | 195 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 2 | 1987 | 115 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 302 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 96 | 0.070 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2008 | 9 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2012 | 98 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 556 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 1988 | 291 | 0.070 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1985 | 103 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2020 | 0.070 |
Why?
|
| Chlorambucil | 2 | 1984 | 13 | 0.070 |
Why?
|
| Drug Administration Schedule | 7 | 2009 | 827 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 1992 | 28 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2007 | 5 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2006 | 1054 | 0.060 |
Why?
|
| Disease-Free Survival | 5 | 2012 | 1171 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2018 | 3497 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2479 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2007 | 33 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 581 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 5 | 1992 | 48 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2014 | 54 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 101 | 0.060 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 74 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 150 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2007 | 941 | 0.060 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Thrombocytosis | 2 | 1996 | 7 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2004 | 80 | 0.060 |
Why?
|
| Bone Marrow Diseases | 4 | 2015 | 37 | 0.060 |
Why?
|
| Cisplatin | 1 | 1987 | 567 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 651 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2002 | 106 | 0.050 |
Why?
|
| Lung Neoplasms | 4 | 1987 | 2363 | 0.050 |
Why?
|
| Mice | 5 | 2015 | 12230 | 0.050 |
Why?
|
| Neutrophils | 6 | 1997 | 324 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1786 | 0.050 |
Why?
|
| Cladribine | 1 | 2003 | 29 | 0.050 |
Why?
|
| Fibrosis | 2 | 1996 | 228 | 0.050 |
Why?
|
| Base Sequence | 4 | 2012 | 2207 | 0.050 |
Why?
|
| Skin Diseases | 1 | 1984 | 173 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2002 | 51 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2012 | 1719 | 0.050 |
Why?
|
| Europe | 2 | 2001 | 338 | 0.050 |
Why?
|
| Leukemia, B-Cell | 1 | 2002 | 22 | 0.050 |
Why?
|
| Chromosomes, Human, 13-15 | 4 | 1985 | 18 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1982 | 20 | 0.050 |
Why?
|
| Retrospective Studies | 11 | 2008 | 10128 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 2484 | 0.040 |
Why?
|
| Liver | 5 | 1989 | 1206 | 0.040 |
Why?
|
| Anemia, Aplastic | 3 | 2015 | 31 | 0.040 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1981 | 11 | 0.040 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 24 | 0.040 |
Why?
|
| Staining and Labeling | 6 | 2001 | 155 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2001 | 128 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1992 | 64 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 156 | 0.040 |
Why?
|
| Antigens, CD | 3 | 1991 | 476 | 0.040 |
Why?
|
| Phenotype | 3 | 2015 | 2545 | 0.040 |
Why?
|
| Ki-1 Antigen | 2 | 1990 | 19 | 0.040 |
Why?
|
| Disease Progression | 3 | 2006 | 1529 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1998 | 184 | 0.040 |
Why?
|
| Hepatitis C | 1 | 1982 | 181 | 0.040 |
Why?
|
| Lymphocytes | 4 | 1995 | 453 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1909 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2001 | 68 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 1996 | 8 | 0.040 |
Why?
|
| International Cooperation | 1 | 2000 | 132 | 0.040 |
Why?
|
| Time Factors | 7 | 2003 | 5380 | 0.040 |
Why?
|
| Animals | 5 | 2015 | 27973 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2006 | 984 | 0.030 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 1998 | 20 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2009 | 4546 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1998 | 106 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 4 | 2002 | 1385 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 885 | 0.030 |
Why?
|
| Platelet Count | 3 | 1989 | 90 | 0.030 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 3 | 1985 | 6 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1994 | 107 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 1995 | 224 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1998 | 351 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 1703 | 0.030 |
Why?
|
| Age Factors | 3 | 2008 | 1898 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 1996 | 5 | 0.030 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 161 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2016 | 50 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 13 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2015 | 18 | 0.030 |
Why?
|
| Drug Therapy, Combination | 5 | 1997 | 753 | 0.030 |
Why?
|
| Chromosomes, Human, 19-20 | 3 | 1986 | 4 | 0.030 |
Why?
|
| Young Adult | 3 | 2014 | 6922 | 0.030 |
Why?
|
| Chromosome Banding | 6 | 1991 | 66 | 0.030 |
Why?
|
| Leukemia, Mast-Cell | 2 | 2008 | 5 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 119 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 2889 | 0.030 |
Why?
|
| Aziridines | 2 | 2005 | 9 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 1994 | 888 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 58 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 89 | 0.030 |
Why?
|
| Benzoquinones | 2 | 2005 | 26 | 0.030 |
Why?
|
| Mitoxantrone | 2 | 2005 | 65 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1994 | 14 | 0.030 |
Why?
|
| Cytogenetic Analysis | 2 | 2006 | 70 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1991 | 19 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1994 | 22 | 0.030 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 15 | 0.030 |
Why?
|
| Decision Making | 1 | 2000 | 671 | 0.030 |
Why?
|
| Splenic Neoplasms | 1 | 1994 | 17 | 0.030 |
Why?
|
| Chromosomes, Human, 4-5 | 2 | 1986 | 7 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2007 | 543 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2014 | 82 | 0.030 |
Why?
|
| Acid Phosphatase | 4 | 1988 | 28 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 134 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 1339 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1993 | 7 | 0.030 |
Why?
|
| HTLV-I Infections | 1 | 1993 | 5 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1994 | 244 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 85 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 1994 | 107 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 1992 | 32 | 0.020 |
Why?
|
| Infusions, Intravenous | 3 | 2003 | 400 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2004 | 59 | 0.020 |
Why?
|
| Incidence | 2 | 1994 | 1697 | 0.020 |
Why?
|
| Digestive System | 2 | 1984 | 41 | 0.020 |
Why?
|
| Gene Rearrangement | 2 | 1990 | 168 | 0.020 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2012 | 20 | 0.020 |
Why?
|
| Animal Diseases | 1 | 1992 | 5 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 891 | 0.020 |
Why?
|
| Cell Division | 2 | 1990 | 689 | 0.020 |
Why?
|
| Neoplasms | 3 | 2004 | 3168 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2012 | 77 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2014 | 601 | 0.020 |
Why?
|
| Blood Cell Count | 4 | 1987 | 65 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 156 | 0.020 |
Why?
|
| Recurrence | 2 | 2004 | 1188 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1990 | 16 | 0.020 |
Why?
|
| Heterozygote | 1 | 1992 | 381 | 0.020 |
Why?
|
| Lymphocytosis | 1 | 1990 | 11 | 0.020 |
Why?
|
| Animals, Zoo | 1 | 1992 | 75 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2121 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1991 | 127 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1990 | 50 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1984 | 121 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1990 | 72 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 242 | 0.020 |
Why?
|
| Basophils | 2 | 1985 | 26 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1990 | 202 | 0.020 |
Why?
|
| Risk Factors | 3 | 2004 | 5900 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1990 | 424 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1060 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1988 | 226 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 1985 | 60 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2005 | 888 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 175 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 206 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2008 | 154 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 1983 | 429 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 312 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1994 | 3044 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 655 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 97 | 0.020 |
Why?
|
| Kidney | 2 | 1984 | 1093 | 0.020 |
Why?
|
| Cytogenetics | 2 | 1991 | 27 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2009 | 360 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1991 | 1447 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1992 | 194 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2827 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2008 | 220 | 0.020 |
Why?
|
| United States | 1 | 2000 | 7581 | 0.020 |
Why?
|
| Interphase | 3 | 1991 | 36 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 2000 | 336 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2003 | 2009 | 0.020 |
Why?
|
| Cat-Scratch Disease | 1 | 1986 | 1 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1986 | 11 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1986 | 37 | 0.010 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1986 | 25 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2003 | 913 | 0.010 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1985 | 19 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1989 | 1051 | 0.010 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2005 | 17 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 34 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2007 | 672 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1129 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 1126 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 1719 | 0.010 |
Why?
|
| Random Allocation | 2 | 1987 | 308 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 302 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1727 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 391 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 300 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 20 | 0.010 |
Why?
|
| Leukopenia | 1 | 1984 | 64 | 0.010 |
Why?
|
| Lymphokines | 1 | 1984 | 74 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3431 | 0.010 |
Why?
|
| Phagocytosis | 3 | 1980 | 111 | 0.010 |
Why?
|
| Autopsy | 1 | 1984 | 126 | 0.010 |
Why?
|
| Aneuploidy | 2 | 1981 | 59 | 0.010 |
Why?
|
| Osteolysis | 1 | 1984 | 10 | 0.010 |
Why?
|
| Respiratory System | 1 | 1984 | 117 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1984 | 42 | 0.010 |
Why?
|
| Neck | 1 | 1984 | 97 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1984 | 60 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 127 | 0.010 |
Why?
|
| Granulocytes | 1 | 1983 | 34 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 727 | 0.010 |
Why?
|
| Hematocrit | 1 | 1983 | 65 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 246 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 217 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 244 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 78 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 469 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 284 | 0.010 |
Why?
|
| Organ Size | 1 | 1983 | 360 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1982 | 91 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1982 | 52 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 278 | 0.010 |
Why?
|
| Rituximab | 1 | 2002 | 129 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 359 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2001 | 31 | 0.010 |
Why?
|
| Tryptases | 1 | 2001 | 11 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 2001 | 6 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 2001 | 22 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2001 | 15 | 0.010 |
Why?
|
| Viscera | 1 | 2001 | 19 | 0.010 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2001 | 8 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 382 | 0.010 |
Why?
|
| Skin | 2 | 2001 | 575 | 0.010 |
Why?
|
| Mast Cells | 1 | 2001 | 96 | 0.010 |
Why?
|
| Clone Cells | 1 | 2001 | 219 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1240 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2001 | 132 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 161 | 0.010 |
Why?
|
| North America | 1 | 2001 | 197 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 638 | 0.010 |
Why?
|
| Syndrome | 1 | 1981 | 432 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 148 | 0.010 |
Why?
|
| Immunologic Capping | 1 | 1980 | 10 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 148 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2001 | 159 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 271 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 381 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 341 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1991 | 231 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1989 | 109 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 688 | 0.010 |
Why?
|
| Sex Factors | 1 | 1982 | 1102 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1908 | 0.010 |
Why?
|
| Reticulin | 1 | 1978 | 2 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1978 | 11 | 0.010 |
Why?
|
| B-Lymphocytes | 3 | 1991 | 703 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 1849 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1981 | 317 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 1139 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1996 | 27 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 288 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 46 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 134 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 313 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 1975 | 9 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1980 | 0.010 |
Why?
|
| Monosomy | 1 | 1995 | 12 | 0.010 |
Why?
|
| Abdomen | 1 | 1975 | 118 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
| Biomarkers | 1 | 2001 | 1905 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1975 | 169 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1975 | 183 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 68 | 0.010 |
Why?
|
| Brain | 1 | 1984 | 2337 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 2465 | 0.010 |
Why?
|
| Cytoplasmic Granules | 3 | 1980 | 94 | 0.010 |
Why?
|
| Monocytes | 2 | 1985 | 214 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1993 | 199 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1992 | 9 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 528 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 550 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 239 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1993 | 234 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1992 | 88 | 0.010 |
Why?
|
| Lung | 1 | 1979 | 1359 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1988 | 1098 | 0.010 |
Why?
|
| Bufonidae | 1 | 1992 | 2 | 0.010 |
Why?
|
| Hedgehogs | 1 | 1992 | 2 | 0.010 |
Why?
|
| Lions | 1 | 1992 | 3 | 0.010 |
Why?
|
| Snakes | 1 | 1992 | 9 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 145 | 0.010 |
Why?
|
| CD11 Antigens | 1 | 1991 | 14 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1991 | 13 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1991 | 33 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1991 | 108 | 0.010 |
Why?
|
| Pentostatin | 1 | 1990 | 13 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 883 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1992 | 319 | 0.010 |
Why?
|
| X Chromosome | 1 | 1991 | 154 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1992 | 255 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1990 | 61 | 0.000 |
Why?
|
| DNA Probes | 1 | 1990 | 66 | 0.000 |
Why?
|
| Birds | 1 | 1992 | 172 | 0.000 |
Why?
|
| Lymphoma, Follicular | 1 | 1990 | 73 | 0.000 |
Why?
|
| Metaphase | 2 | 1980 | 20 | 0.000 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 1980 | 29 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 266 | 0.000 |
Why?
|
| Centromere | 1 | 1988 | 27 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1989 | 188 | 0.000 |
Why?
|
| Leukocytes | 2 | 1980 | 210 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1986 | 14 | 0.000 |
Why?
|
| Francisella | 1 | 1986 | 1 | 0.000 |
Why?
|
| Haemophilus | 1 | 1986 | 1 | 0.000 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1986 | 8 | 0.000 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1986 | 12 | 0.000 |
Why?
|
| Antitubercular Agents | 1 | 1986 | 61 | 0.000 |
Why?
|
| Erythrocyte Transfusion | 1 | 1986 | 74 | 0.000 |
Why?
|
| Mitosis | 2 | 1976 | 151 | 0.000 |
Why?
|
| Lymphopenia | 1 | 1985 | 31 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 1260 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1986 | 171 | 0.000 |
Why?
|
| Colony-Stimulating Factors | 1 | 1984 | 13 | 0.000 |
Why?
|
| Immune Sera | 1 | 1984 | 48 | 0.000 |
Why?
|
| Interleukin-3 | 1 | 1984 | 39 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1984 | 51 | 0.000 |
Why?
|
| Thymidine | 1 | 1984 | 58 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1986 | 156 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1984 | 145 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1985 | 189 | 0.000 |
Why?
|
| Retroviridae Infections | 1 | 1984 | 43 | 0.000 |
Why?
|
| Mutagens | 1 | 1982 | 29 | 0.000 |
Why?
|
| Insecticides | 1 | 1982 | 26 | 0.000 |
Why?
|
| Solvents | 1 | 1982 | 91 | 0.000 |
Why?
|
| Metals | 1 | 1982 | 101 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1981 | 140 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1981 | 73 | 0.000 |
Why?
|
| Zymosan | 1 | 1980 | 2 | 0.000 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1980 | 3 | 0.000 |
Why?
|
| Lectins | 1 | 1980 | 82 | 0.000 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 1980 | 5 | 0.000 |
Why?
|
| Tartrates | 1 | 1980 | 5 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1980 | 22 | 0.000 |
Why?
|
| Butyrates | 1 | 1980 | 56 | 0.000 |
Why?
|
| Quinacrine | 1 | 1978 | 10 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1978 | 43 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1978 | 28 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1980 | 253 | 0.000 |
Why?
|
| Sex Chromosomes | 1 | 1978 | 56 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1978 | 40 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1980 | 661 | 0.000 |
Why?
|
| Quinacrine Mustard | 1 | 1976 | 1 | 0.000 |
Why?
|
| Chromosomes | 1 | 1976 | 91 | 0.000 |
Why?
|
| Macrophages | 1 | 1975 | 609 | 0.000 |
Why?
|